In particular, genetic heterogeneity, such as decreased hENT1 expression and the presence of cancer stem cells (CSCs), as well as TME factors, including fibrosis induced by cancer-associated fibroblasts (CAFs) and a hypoxic environment, contribute to drug resistance. Here, SLC29A1 is linked to cancer.